Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 13/20 | 0.71 |
| ▸ | CA2 | P00918 | 13/20 | 0.71 |
| ▸ | CA9 | Q16790 | 13/20 | 0.71 |
| ▸ | CA12 | O43570 | 12/20 | 0.71 |
| ▸ | CA7 | P43166 | 9/20 | 0.71 |
| ▸ | TSHR | P16473 | 1/20 | 0.71 |
| ▸ | CA4 | P22748 | 6/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.56 |
| ▸ | CA5A | P35218 | 3/20 | 0.56 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29948540 | 0.95 | CA1 (0.65) | CA1CA2CA9CA12CA7 | |
| SCHEMBL28457987 | 0.91 | CA1 (0.74) | CA1CA2CA9CA12CA7 | |
| SCHEMBL18361753 | 0.88 | CA1 (0.56) | CA1CA2CA9CA12CA7 | |
| SCHEMBL18361762 | 0.83 | HRH3 (0.52) | CA1CA2CA9CA12CA7 | |
| SCHEMBL12219721 | 0.83 | CA12 (0.49) | CA1CA2CA9CA12CA7 | |
| SCHEMBL5595956 | 0.83 | CA1 (1.00) | CA1CA2CA9CA12CA7 | |
| SCHEMBL615392 | 0.83 | CA2 (1.00) | CA1CA2CA9CA12CA7 | |
| SCHEMBL14058897 | 0.82 | LMNA (0.51) | CA1CA2CA9CA12CA7 | |
| SCHEMBL19891669 | 0.82 | CA12 (0.79) | CA1CA2CA9CA12CA7 | |
| SCHEMBL6393911 | 0.81 | CA12 (0.47) | CA1CA2CA9CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606522-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | ORSOBIO, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20240409508-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | ORSOBIO, INC. | 2024-12-12 | — | — | US | disclosed |
| CN-118791407-A | Sulfinylamino group benzamide and process for preparing same Sulfonylamino benzamide derivatives | 奥索生物公司 | 2024-10-18 | — | — | CN | disclosed |
| CN-118638096-A | Sulfinylamino group benzamide and process for preparing same Sulfonylamino benzamide derivatives | 奥索生物公司 | 2024-09-13 | — | — | CN | disclosed |
| US-12049439-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | ORSOBIO, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| CN-112204008-B | Sulfonylaminobenzamides and sulfonylaminobenzamide derivatives | 奥索生物公司 | 2024-07-05 | — | — | CN | disclosed |
| EP-3796975-B1 | SULFONYLAMINOBENZAMIDE DERIVATIVES | ORSOBIO INC (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20220055985-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | GILEAD SCIENCES, INC. | 2022-02-24 | — | — | US | disclosed |
| US-11136290-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | THE LIVER COMPANY INC. (US) | 2021-10-05 | — | — | US | disclosed |
| EP-3796975-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | GILEAD SCIENCES, INC. (US) | 2021-03-31 | — | — | EP | disclosed |
| CN-112204008-A | Sulphonylaminobenzylamide and sulphonylaminobenzamide derivatives | 吉利德科学公司 | 2021-01-08 | — | — | CN | disclosed |
| CN-107098846-B | N-acyl sulfonamide FBPase inhibitor, preparation method thereof, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2020-10-09 | — | — | CN | disclosed |
| EP-0510526-B1 | Use of sulfonamides as drug and new sulfonamides | HOFFMANN LA ROCHE (CH) | 1996-12-04 | — | — | EP | disclosed |
| US-5270313-A | Treatment of circulatory disorders | HOFFMANN-LA ROCHE INC. (US) | 1993-12-14 | — | — | US | disclosed |
| EP-0510526-A1 | Use of sulfonamides as drug and new sulfonamides | F.HOFFMANN-LA ROCHE & CO. AKTIENGESELLSCHAFT (CH) | 1992-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220055985-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | STS, SULT2A1, SCN2B | CA1 2349/4885CA2 1775/4885CA9 1512/4885 |
| US-12049439-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | STS, SULT2A1, SCN2B | CA1 2349/4885CA2 1775/4885CA9 1512/4885 |
| US-12606522-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | NR3C2, NR5A1, SRD5A2 | CA1 3778/4885CA2 3086/4885CA9 1910/4885 |
| US-20240409508-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | STS, SULT2A1, SCN2B | CA1 2349/4885CA2 1775/4885CA9 1512/4885 |
| US-11136290-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | STS, SULT2A1, SCN2B | CA1 2349/4885CA2 1775/4885CA9 1512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.